P3 Health Partners shares fall 14.63% premarket following weak Q3 2025 earnings and outlook reset.

P3 Health Partners Inc. (PIII) fell 14.63% in premarket trading, driven by weak third-quarter 2025 earnings results and a revised outlook highlighted in recent reports. Analysts noted Q3 performance below expectations, with challenges in navigating growth amid operational pressures. Additionally, TD Cowen lowered PIII’s price target from $12.50 to $8, signaling reduced confidence in the stock’s valuation. Despite prior positive developments, such as a joint venture expansion with Commonwealth Primary Care ACO, the recent earnings miss and bearish analyst revisions overshadowed other news, prompting the sharp premarket decline.